Blog
view all
News
- Sunday, December 7th - A Problem Rises to the Surface in Greenpoint
- Friday, December 5th - Warning Given on Use of 4 Popular Asthma Drugs, but Debate Remains.
- Wednesday, October 1st - Wrongful Death Settlement Reached $28M in Big Dig Tunnel Deal
- Wednesday, October 1st - Healthcare Abroad, Also known as Medical Tourism, ss Growing in Popularity
- Monday, Monday 22nd - Chantix Banned for Airline Pilots Due to Links of Auto Accidents
- Monday, Monday 22nd - $6 Million Wrongful Death Settlement Issued from 2004 Collision
- Tuesday, September 16th - Barclays May Rescue Part of Lehman Brothers
- Tuesday, September 16th - Change in Labor Law
- Monday, September 8th - Wrongful Death Case of a Policeman Settles at $2 Million
- Monday, September 8th - List of Drugs with Suicidal Tendencies
- Monday, September 1st - After Crib Recall for Simplicity Still Produces Faulty Products
- Monday, September 1st - Faulty Baby Sleepsafe Monitors
view all
Library
Napoli Bern Ripka, LLP Library
On the page below you can find links to documents, reports, publications and discussions provided by Napoli Bern LLP.
The documents below are available to the public so that they can gain a better understanding of the legal challenges facing them, and why an experienced attorney is so important for success.
Contact us for a consultation today.
FDA and Prescription Drugs
- Avandia
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. - Ancure
Ancure is a synthetic graft device that is used to repair abdominal aortic aneurysms. In March 2001 Guidant, the company that manufactures Ancure, suspended production of the device and announced a recall of all existing Ancure inventory. Contact Napoli Bern if you have had this procedure. - Baycol
Baycol, one of a family of popular cholesterol-lowering drugs, was pulled from the U.S. market by its manufacturer because of reports linking the pill to 31 deaths. Contact Napoli Bern if you have been injured by Baycol. - Fen-Phen
"Fen-Phen," the popular name for the combination of the drugs fenfluramine (Pondimin) and phentermine, has been on the market in the United States for several decades. Doctors prescribed the drug combination to help control obesity. - Fosamax
Fosamax, also known as alendronate, is an osteoporosis drug manufactured by Merck & Company. Since Alendronate is a bisphosphonate, it may help to reduce bone fractures (by increasing bone mass for instance). - Ortho Evra
Ortho Evra is the first transdermal (skin) patch approved for birth control. The weekly prescription patch releases norelgestromin (a progestin hormone), and ethinyl estradiol (an estrogen hormone), through the skin into the blood stream to prevent pregnancy. The U.S. Food and Drug Administration approved Ortho Evra, manufactured by Ortho McNeil, a subsidiary of Johnson & Johnson, in November 2001. - Guidant Defibrillators and Pacemakers
FDA is notifying health care providers and patients that the Guidant Corporation is recalling certain of its implantable defibrillators and cardiac resynchronization therapy defibrillators. These devices can develop an internal short circuit without warning, resulting in failure to deliver a shock when needed. - Primary Pulmonary Hypertension
The legal definition of primary pulmonary hypertension (also known as PPH, idiopathic pulmonary hypertension, and pulmonary hypertension) is a rare condition in which the blood pressure in the arteries of the lungs is abnormally high. The condition is often fatal and is primarily found in female patients aged 20-40 years old. The cause of primary pulmonary hypertension is unknown. It is considered a progressive disease, often leading to congestive heart failure, respiratory failure, and eventually death. - Seroquel
Seroquel, also known as quetiapine fumarate, is an antipsychotic used to treat schizophrenia and symptoms of psychotic disorders such as hallucinations, delusions, and hostility. The U.S. Food and Drug Administration (FDA) approved Seroquel in 1997. - Serzone
Serzone, also known as nefazodone hydrochloride, belongs to a class of medications known as antidepressants. Manufactured by Bristol-Meyers Squibb Company, Serzone fights mental depression by increasing natural substances in the brain. The U.S. Food and Drug Administration approved Serzone in 1994. - Trasylol
Trasylol is manyfactured by Bayer Pharmaceuticals and is designed for patients who undergo Cardiopulmonary Bypass (CPB) for Coronary Artery Bypass Graft (CABG) surgery. Trasylol has been linked to adverse events including stroke, encephalopathy, heart attack and kidney damage, and studies have shown that there are cheaper and safer generic options options available. - Medtronic Defibrillators
Medtronic and the Food and Drug Administration (FDA) have issued statements that Medtronic is voluntarily removing its Sprint Fidelis defibrillation leads from the market as the electrical wires are “prone to fracture in a small number of patients which can cause the defibrillator to deliver unnecessary shocks or not operate at all.” - Gardasil
It all started 2 years ago when Merck & Co. started administering Gardasil, a cervical-cancer vaccine, to girls and women. Over 8,000 adverse reactions have been recorded by the Federal health officials. Gardasil was licensed by the Food and Drug Administration in June 2006 for females ages 9 to 26. Sold worldwide, it's been given to more than 8 million US girls and women, Merck says. The vaccine is aimed at warding off strains of the human papillomavirus, or HPV, which can lead to cancer. The vaccinations cost a total $360. Securities and Exchange Commission documents show Merck made $1.5 billion in Gardasil sales last year.
Recruiting
- Careers
Napoli Bern Ripka, LLP is interested in only the finest legal talent in New York. We have expanded our offices with seasoned litigators, law students, and paralegals.
Newsletter
General
